These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 19704027)

  • 1. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.
    Hagihara K; Kazui M; Kurihara A; Yoshiike M; Honda K; Okazaki O; Farid NA; Ikeda T
    Drug Metab Dispos; 2009 Nov; 37(11):2145-52. PubMed ID: 19704027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs.
    Hagihara K; Kazui M; Ikenaga H; Nanba T; Fusegawa K; Takahashi M; Kurihara A; Okazaki O; Farid NA; Ikeda T
    Xenobiotica; 2009 Mar; 39(3):218-26. PubMed ID: 19280520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiolactone sulfoxides as new reactive metabolites acting as bis-electrophiles: implication in clopidogrel and prasugrel bioactivation.
    Dansette PM; Levent D; Hessani A; Bertho G; Mansuy D
    Chem Res Toxicol; 2013 May; 26(5):794-802. PubMed ID: 23527615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel.
    Nishiya Y; Hagihara K; Ito T; Tajima M; Miura S; Kurihara A; Farid NA; Ikeda T
    Drug Metab Dispos; 2009 Mar; 37(3):589-93. PubMed ID: 19047469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
    Farid NA; Kurihara A; Wrighton SA
    J Clin Pharmacol; 2010 Feb; 50(2):126-42. PubMed ID: 19948947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel.
    Chen CH; Yang JC; Uang YS; Lin CJ
    Biopharm Drug Dispos; 2012 Jul; 33(5):278-83. PubMed ID: 22623337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
    Brandt JT; Payne CD; Wiviott SD; Weerakkody G; Farid NA; Small DS; Jakubowski JA; Naganuma H; Winters KJ
    Am Heart J; 2007 Jan; 153(1):66.e9-16. PubMed ID: 17174640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite.
    Hagihara K; Kazui M; Kurihara A; Iwabuchi H; Ishikawa M; Kobayashi H; Tanaka N; Okazaki O; Farid NA; Ikeda T
    Drug Metab Dispos; 2010 Jun; 38(6):898-904. PubMed ID: 20228231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.
    Jakubowski JA; Winters KJ; Naganuma H; Wallentin L
    Cardiovasc Drug Rev; 2007; 25(4):357-74. PubMed ID: 18078435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel.
    Nishiya Y; Hagihara K; Kurihara A; Okudaira N; Farid NA; Okazaki O; Ikeda T
    Xenobiotica; 2009 Nov; 39(11):836-43. PubMed ID: 19845434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic basis of the antiplatelet action of prasugrel.
    Schrör K; Siller-Matula JM; Huber K
    Fundam Clin Pharmacol; 2012 Feb; 26(1):39-46. PubMed ID: 21895761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
    Payne CD; Li YG; Small DS; Ernest CS; Farid NA; Jakubowski JA; Brandt JT; Salazar DE; Winters KJ
    J Cardiovasc Pharmacol; 2007 Nov; 50(5):555-62. PubMed ID: 18030066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer.
    Dansette PM; Rosi J; Bertho G; Mansuy D
    Chem Res Toxicol; 2012 Feb; 25(2):348-56. PubMed ID: 22103858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
    Dobesh PP
    Pharmacotherapy; 2009 Sep; 29(9):1089-102. PubMed ID: 19698014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The intestine as an important contributor to prasugrel active metabolite formation in vivo.
    Hagihara K; Kazui M; Ikenaga H; Nanba T; Fusegawa K; Izumi T; Ikeda T; Kurihara A
    Drug Metab Dispos; 2011 Apr; 39(4):565-70. PubMed ID: 21189331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formation and fate of a sulfenic acid intermediate in the metabolic activation of the antithrombotic prodrug prasugrel.
    Dansette PM; Thébault S; Bertho G; Mansuy D
    Chem Res Toxicol; 2010 Jul; 23(7):1268-74. PubMed ID: 20557086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the metabolism of clopidogrel and prasugrel.
    Laizure SC; Parker RB
    Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1417-24. PubMed ID: 20839914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.
    Wallentin L; Varenhorst C; James S; Erlinge D; Braun OO; Jakubowski JA; Sugidachi A; Winters KJ; Siegbahn A
    Eur Heart J; 2008 Jan; 29(1):21-30. PubMed ID: 18055486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
    Farid NA; Payne CD; Small DS; Winters KJ; Ernest CS; Brandt JT; Darstein C; Jakubowski JA; Salazar DE
    Clin Pharmacol Ther; 2007 May; 81(5):735-41. PubMed ID: 17361128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic activation of prasugrel: nature of the two competitive pathways resulting in the opening of its thiophene ring.
    Dansette PM; Rosi J; Debernardi J; Bertho G; Mansuy D
    Chem Res Toxicol; 2012 May; 25(5):1058-65. PubMed ID: 22482514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.